A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

Exclusion Criteria

• •1. Patient who has been administered with intrathecal Idursulfase in the past
• •2. Patient with a history of bone marrow transplantation or cord blood transplant
• •3. Patient with a history of ventriculoperitoneal shunt or other intracranial surgeries
• •4. Patient with end-stage multiple organ dysfunction syndrome or other severe diseases
• •5. Patient who is exposed to malignant neoplasm
• •6. Patient who has received treatment with any investigational drug or device within 30 days prior to study entry
• •7. Patient who have experience of hypersensitivity or anaphylaxis to ingredients of the investigational product at the time of screening
• •8. Patient with a history of bronchotomy/tracheostomy, or patient with acute respiratory disease at the time of screening
• •9. Patient who is ineligible to participate in the clinical trial due to laboratory test results or other reasons, as determined by the investigator